IGF-1 is an Independent Risk Factor for Anemia in Diabetic Pre-dialysis Patients
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background : We investigated whether the presence of diabetes mellitus (DM) was related to the degree of the anemia in predialytic patients with renal failure and what was the most relevant factor for anemia in patients with chronic kidney disease (CKD) from DM (DM-CKD). Methods : Seventy seven patients (47 predialytic patients with long-term type 2 DM (DM-CKD) and 30 predialytic patients whose disease was due to other causes (non DM-CKD)) were enrolled in this study. The blood hemoglobin (Hb) and hematocrit, and the creatinine, ferritin, vitamin B12, folate, iron, LDH, albumin, hs-CRP, intact-PTH, erythropoietin, leptin and Insulin-like growth factor I (IGF-1) levels were measured using standard methods. The estimated GFR was calculated using the abbreviated MDRD equation. Results : The two groups did not significantly differ as to age, gender, the serum creatinine level and the inflammatory status. The Hb level was significantly lower in the DM-CKD patients than that in the non DM-CKD patients (8.5±1.7 g/dL vs 9.6±1.6 g/dL, respectively, p=0.01). The Hb level was significantly lower in the DM-CKD patients who were being treated with ACE inhibitors (the DM-ACE patients) than that in the non DM-CKD patients who were being treated with ACE inhibitors (the non DM-ACE patients) (8.5±1.5 g/dL vs 10.8±1.6 g/dL, respectively, p=0.001). Multiple regression analysis indicated that serum IGF-1 concentration was independently associated with the Hb level (β=0.425, p=0.02) in the DM-CKD patients. Conclusions : The Hb concentration was significantly lower in the DM-CKD patients than that in the non DM-CKD patients. It was independently associated with the serum IGF-1 concentration in the DM-CKD patients.
Abstract
Background : We investigated whether the presence of diabetes mellitus (DM) was related to the degree of the anemia in predialytic patients with renal failure and what was the most relevant factor for anemia in patients with chronic kidney disease (CKD) from DM (DM-CKD). Methods : Seventy seven patients (47 predialytic patients with long-term type 2 DM (DM-CKD) and 30 predialytic patients whose disease was due to other causes (non DM-CKD)) were enrolled in this study. The blood hemoglobin (Hb) and hematocrit, and the creatinine, ferritin, vitamin B12, folate, iron, LDH, albumin, hs-CRP, intact-PTH, erythropoietin, leptin and Insulin-like growth factor I (IGF-1) levels were measured using standard methods. The estimated GFR was calculated using the abbreviated MDRD equation. Results : The two groups did not significantly differ as to age, gender, the serum creatinine level and the inflammatory status. The Hb level was significantly lower in the DM-CKD patients than that in the non DM-CKD patients (8.5±1.7 g/dL vs 9.6±1.6 g/dL, respectively, p=0.01). The Hb level was significantly lower in the DM-CKD patients who were being treated with ACE inhibitors (the DM-ACE patients) than that in the non DM-CKD patients who were being treated with ACE inhibitors (the non DM-ACE patients) (8.5±1.5 g/dL vs 10.8±1.6 g/dL, respectively, p=0.001). Multiple regression analysis indicated that serum IGF-1 concentration was independently associated with the Hb level (β=0.425, p=0.02) in the DM-CKD patients. Conclusions : The Hb concentration was significantly lower in the DM-CKD patients than that in the non DM-CKD patients. It was independently associated with the serum IGF-1 concentration in the DM-CKD patients.
참고문헌 (32)
- Foley RN, "Cardiac disease in diabetic end-stage renal disease", 40, pp.1307~1312 (1997)
- Bosman DR, "Anemia with erythropoietin deficiency occurs early in diabetic nephropathy", 24, pp.495~499 (2001)
- Ishimura E, "Diabetes mellitus increases the severity of anemia in non-dialyzed patients with renal failure", 11, pp.83~86 (1998)
- Nephrol Dial Transplant, "European Best Practice Guidelines for the management of anemia in patients with chronic renal failure: Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure", 14, pp.1~50 (1999)
- Eschbach JW, "Treatment of the anemia of progressive renal failure with recombinant human erythropoietin", pp.158~163 (1989)
- Spivak JL, "Serum immunoreactive erythropoietin in health and disease", 23, pp.13~17 (1995)
- Winearls CG, "Historical review on the use of recombinant human erythropoietin in chronic renal failure", 10, pp.3~9 (1995)
- Eschbach JW, "implications for nephrology", pp.203~209 (1988)
- Danielson B, "RHuEPO hyporesponsiveness: - who and why?", 10, pp.69~73 (1995)
- Drueke TB, "RHuEPO hyporesponsiveness: - who and why?", 10, pp.62~68 (1995)
- Chaplin H Jr, "Red cell life span in nephritis and in hepatic cirrhosis", pp.351~360 (1953)
- Fukushima Y, "The inhibitory factors of hematopoiesis in chronic hemodialysis patients treated with recombinant human erythropoietin", pp.217~225 (1990)
- Eschbach JW, "Correction of the anemia of end-stage renal disease with recombinant human erythropoietin results of a combined phase I and II clinical trial", pp.73~78 (1987)
- Correa PN, "Production of erythropoietic bursts by progenitor cells from adult human peripheral blood in an improved serum-free medium role of insulinlike growth factor 1", pp.2823~2833 (1991)
- Deicher R, "Hormonal adjuvants for the treatment of renal anemia", 35, pp.75~84 (2005)
- Axelsson J, "Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD", 46, pp.628~634 (2005)
- Levey AS, "A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation", 130, pp.461~470 (1999)
- White KE, "Type 2 diabetic patients with nephropathy show structural-functional relationships that are similar to type 1 disease", 11, pp.1667~1673 (2000)
- Keane WF, "The risk of developing endstage renal disease in patients with type 2 diabetes and nephropathy", 63, pp.1499~1507 (2003)
- N Engl J Med 329, "Treatment of orthostatic hypotension with erythropoietin", pp.611~615 (1993)
- Ghirlanda G, "Erythropoietin depletion and anemia in diabetes mellitus", 17, pp.410~ (2000)
- RanmaniJourdheuil D, "In vivo insulin effect on ATPase activities in erythrocyte membrane from insulindependent diabetics", pp.991~36 995 (1987)
- "Changes in fluidity and composition of erythrocyte membranes and in composition of plasma lipids in type I diabetes", pp.111~116 (1986)
- Jones RH, "a review of sixty-three years of medical research and a glimpse into the future? Horm Res 40", pp.68~79 (1993)
- Thraikill KM, "Insulin-like growth factor-1 in diabetes mellitus: its physiology, metabolic effects, and potential clinical utility", 2, pp.69~80 (2000)
- Garay-Sevilla ME, "Advanced glycosylation end products, insulin-like growth factor-1 and IGF-binding protein-3 in patients with type 2 diabetes mellitus", 16, pp.106~113 (2000)
- Brox AG, "Subtherapeutic erythropoietin and insulin-like growth factor-1 correct the anemia of chronic renal failure in the mouse", 50, pp.937~943 (1996)
- Shih LY, "Insulin-like growth factor 1 plays a role in regulating erythropoiesis in patients with end-stage renal disease and erythrocytosis", 10, pp.315~322 (1999)
- "Worsening of anemia by angiotensin converting inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients", o sa(yama k i t), pp.3~ (1989)
- Honkanen T, "High serum erythropoietin levels are normalized during treatment of congestive heart failure with enalapril", pp.257~260 (1989)
- Am J Kidney Dis 17, "Enalapril- associated anemia in renal transplant patients treated for hypertension"
- Morrone LF, "Interference of angiotensin-converting inhibitors on erythropoiesis in kidney transplant recipients: role of growth factors and cytokines", 64, pp.913~918 (1997)